HYPERKALEMIA TREATMENT MARKET ANALYSIS

Hyperkalemia Treatment Market, by Drug Type (IV Calcium, Insulin, Sodium Bicarbonate, Beta2 Agonist, Diuretics, Sodium Polystyrene Sulfonate, Others), by Route of Administration (Oral and Intravenous, Inhalation, Rectal), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI2406
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Hyperkalemia Treatment Market – Regional Insights

On the basis of geography, the global hyperkalemia treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global hyperkalemia treatment market followed by Europe during the forecast period.

The U.S. holds a dominant position in North America market due to development in healthcare infrastructure, and Unhealthy lifestyle of U.S of citizen. As incidence of hyperkalemia has been reported anywhere from 2.6% to 3.2% which is highest among others region.

Furthermore, Asia Pacific hyperkalemia treatment market is expected to witness significant growth due increasing launches of drugs for the treatment of hyperkalemia. For instance, In May 2018, The U.S. Food and Drug Administration (U.S FDA) approved AstraZeneca’s, Lokelma a drug that is insoluble, non-absorbed sodium zirconium silicate, oral suspension and acts as a highly-selective potassium-removing agent for the treatment of hyperkalemia in adults.

Similarly, in October 2015, the U.S FDA approved Relypsa, Inc.’s., Veltassa a drug to treat hyperkalemia.